News brief­ing: Spring­Works, Jazz ex­change $35M and PTSD drug; Dr. Red­dy's says cy­ber­at­tack was ran­somware

Jazz Phar­ma­ceu­ti­cals is grab­bing an ex-Pfiz­er drug to beef up its mid-stage neu­ro­science port­fo­lio, pay­ing Spring­Works $35 mil­lion in cash for a new med for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER